Background blur image

Decoding the language of life with foundation models

Blank Bio builds foundation models that understand RNA, the language of life. Their model powers applications across the entire R&D pipeline, from designing better drugs to running smarter clinical trials.Our first model is state-of-the-art in mRNA property prediction. It simulates costly experiments, helping partners design more effective mRNA medicines faster and cheaper. Our open-source models are being used by Sanofi & GSK.

We’re also collaborating with the Arc Institute to bring our RNA embeddings into the next generation of virtual cell models.mRNA design is just the beginning. As the model improves, we’re extending to applications like target ID, novel biomarker discovery, patient stratification, and more. We’ve spent decades applying machine learning to biology across academia (PhDs at the University of Toronto) and industry (Recursion, Deep Genomics, Amazon).

Biotech
Pharmatech
Fund
Fund III
Fund III
Location
San Francisco, CA
Vancouver, BC
Year Invested
2025
Go to Website
Link

Founders

Arrow LeftArrow Right

Jonny Hsu

Co-founder & CEO

Philip Fradkin

Co-founder & CSO

Ian Shi

Co-founder & CTO

Our Story: Ripple Ventures and

Blank Bio

We have known CEO Jonny Hsu through our RippleX network for over five years—he was part of our initial fellowship cohorts—and have tracked his journey closely. While the valuation is higher than any of our prior Fund III entries (roughly 2x), we view this as justified by the scale of the opportunity: RNA has already proven to be a $100B+ modality through vaccine development, and Blank’s horizontal platform approach can reach commercialization faster than traditional biotech business models.

Co Investors

SignalFire, Define Ventures, Leonis Capital, Y Combinator

Work with

Blank Bio

Explore exciting career opportunities with high-growth companies backed by Ripple Ventures.
See Open Positions
Link
Background blur image